Skip to main content
Clinical Trials/NCT02342405
NCT02342405
Completed
Not Applicable

Effect of High Inspiratory Oxygen Fraction on Endothelial Function in Healthy Volunteers: a Randomized Controlled Cross-over Trial

Zealand University Hospital1 site in 1 country25 target enrollmentJanuary 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endothelial Dysfunction
Sponsor
Zealand University Hospital
Enrollment
25
Locations
1
Primary Endpoint
Endothelial dysfunction assessed by the EndoPat-system
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The frequency of preoperative cardiac ischemia and the 30-days postoperative mortality is much higher than previously assumed, with approximately 10 % of patients undergoing non-cardiac surgery suffering from postoperative myocardial injury. A recent danish study furthermore showed that patients treated with a high inspiratory oxygen fraction during surgery had a higher 1 year mortality compared with patients treated with a low inspiratory fraction. This was especially significant among patients undergoing cancer surgery. A possible explanation, is that a high oxygen fraction results in oxidative stress and endothelial dysfunction.

With this randomized cross-over study we wish to investigate the effect of a high inspiratory oxygen fraction on the endothelial function among healthy male volunteers. The primary outcome is the endothelial function assessed by the EndoPat system. Secondary outcomes are changes in oxidative biomarkers. Heart rate variability (HRV) recordings will serve as a measure for the effect of oxygen on the autonomic nervous system.

Registry
clinicaltrials.gov
Start Date
January 2015
End Date
March 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ismail Gögenur

Professor.

Zealand University Hospital

Eligibility Criteria

Inclusion Criteria

  • Healthy male volunteers between 18 and 30 years who has given an oral and written informed consent

Exclusion Criteria

  • Smoking, or ex-smoker Any kind of medication on a daily basis History of atopic dermatitis Known familiar hypercholesterolemia History of arteriosclerotic disease in the first and second-degree relatives Known or unknown arrhythmias, as measured by the baseline HRV-recording

Outcomes

Primary Outcomes

Endothelial dysfunction assessed by the EndoPat-system

Time Frame: After 2 hours of preoxygenation

Changes in baseline pulse-wave-amplitude (PWA) after ischemia-reperfusion from the baseline PWA measurement until 5 minutes after ischemia as a measure of altered endothelial cell function caused by high inspiratory oxygen fractions

Secondary Outcomes

  • Heart rate variability (HRV) after ischemia-reperfusion as a measure of altered balance in the Autonomic nervous system(Baseline measure conducted from baseline until 20 minutes of pre oxygenation. Secondary measures is conducted 20 minutes before withdrawal of the oxygen)
  • Plasma-Malondialdehyde (MDA)(Meaured at baseline, after 2 hours of oxygenation and after 30, 60, 120, 240 minutes after the EndoPat measure)
  • Plasma-Arginine/Asymmetric dimethylarginine(ADMA)(Meaured at baseline, after 2 hours of oxygenation and after 30, 60, 120, 240 minutes after the EndoPat measure)
  • Plasma-Tetrahydrobiopterin(Meaured at baseline, after 2 hours of oxygenation and after 30, 60, 120, 240 minutes after the EndoPat measure)
  • Plasma-Advanced oxidation protein products (AOPP)(Meaured at baseline, after 2 hours of oxygenation and after 30, 60, 120, 240 minutes after the EndoPat measure)
  • Plasma-Ascorbate/Dehydroascorbate (AA/DHA)(Meaured at baseline, after 2 hours of oxygenation and after 30, 60, 120, 240 minutes after the EndoPat measure)

Study Sites (1)

Loading locations...

Similar Trials